Evidence mapPaperPMID 42511630Full record

ReviewInternational journal of molecular sciences2026

Psyllium and Glucomannan as Viscous Fiber Modulators of the Gut-Microbiome-Incretin Axis: Molecular Links to Metabolic Inflammation, Barrier Function, and GLP-1 Receptor Agonist Therapy.

Yonghyun Yoon, Jihyo Hwang, Chan-Mo Yang, Myunghoon Moon, Jong-Jin Lee, King Hei Stanley Lam, Jeimylo C de Castro, Teinny Suryadi, Anwar Suhaimi, Jonghyeok Lee

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yonghyun YoonDepartment of Orthopaedic Surgery, Gangnam Sacred Heart Hospital, Hallym University College of Medicine, 1 Singil-ro, Yeongdeungpo-gu, Seoul 07441, Republic of Korea.ORCID 0000-0001-8746-3718
Jihyo HwangDepartment of Orthopaedic Surgery, Gangnam Sacred Heart Hospital, Hallym University College of Medicine, 1 Singil-ro, Yeongdeungpo-gu, Seoul 07441, Republic of Korea.ORCID 0000-0002-9141-9856
Chan-Mo YangDepartment of Psychiatry, School of Medicine, Wonkwang University, Iksan 54538, Republic of Korea.
Myunghoon MoonNaeuram Clinic, Seoul 05363, Republic of Korea.
Jong-Jin LeeCeramique Clinic, Seoul 06123, Republic of Korea.
King Hei Stanley LamThe Board of Clinical Research, International Academy of Musculoskeletal Medicine, Kowloon, Hong Kong, China.ORCID 0000-0003-1392-829X
Jeimylo C de CastroSMARTMD Center for Non-Surgical Pain Interventions, Makati 1205, Philippines.ORCID 0000-0002-0148-1614
Teinny SuryadiThe Board of Clinical Research, International Academy of Musculoskeletal Medicine, Kowloon, Hong Kong, China.ORCID 0009-0000-6722-0268
Anwar SuhaimiThe Board of Clinical Research, International Academy of Musculoskeletal Medicine, Kowloon, Hong Kong, China.ORCID 0000-0001-5795-0988
Jonghyeok LeeInternational Academy of Regenerative Medicine, Inha-ro 489beon-gil, Namdong-gu, Incheon 21574, Republic of Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dietary fiber is an under-consumed nutritional substrate that supports gut microbial metabolism, intestinal barrier integrity, enteroendocrine signaling, and cardiometabolic regulation. Among dietary fibers, psyllium and glucomannan are clinically accessible viscous, gel-forming soluble fibers with distinct but complementary physicochemical profiles. This narrative review examines how these fibers act through luminal viscosity, nutrient diffusion, bile acid and cholesterol handling, short-chain fatty acid production, epithelial barrier support, enteroendocrine L-cell signaling, and low-grade metabolic inflammation. Psyllium has the strongest clinical support for stool normalization, glycemic modulation, and LDL cholesterol reduction, whereas glucomannan provides marked viscosity and water-holding capacity that may support satiety, lipid modulation, and weight-management strategies when appropriately hydrated and tolerated. We also discuss the emerging nutritional context of glucagon-like peptide-1 receptor agonist therapy, in which appetite suppression, reduced meal volume, delayed gastrointestinal transit, and constipation may reduce dietary fiber intake and fermentable substrate delivery to the colon. The pain- and mood-related implications are framed as hypothesis-generating extensions, because direct clinical evidence that psyllium or glucomannan improves these outcomes remains limited. A psyllium-centered, selectively glucomannan-supported strategy may help close the fiber gap and support bowel function, microbial metabolite signaling, and cardiometabolic stability during modern metabolic and weight-loss therapies.

Indexed as

Dietary FiberGastrointestinal MicrobiomeGlucagon-Like Peptide-1 Receptor AgonistsMannansPsylliumAnimalsGlucagon-Like Peptide-1 ReceptorHumansInflammationIntestinal Barrier FunctionViscosity(1-6)-alpha-glucomannanDietary FiberGlucagon-Like Peptide-1 ReceptorGlucagon-Like Peptide-1 Receptor AgonistsMannansPsylliumcardiometabolic riskdietary fiberenteroendocrine signalingGLP-1 receptor agonistsglucomannangut microbiotaintestinal barrierpsylliumshort-chain fatty acidstype 2 diabetes

Identifiers

PMID42511630
PMCPMC13410363

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.